84-year-old pharma founder sells to young Nigerian entrepreneurs in confidential NAFDAC-licensed deal
A fully licensed Nigerian pharmaceutical manufacturer changed ownership after its 84-year-old founder sold a majority stake to a group of young Nigerian entrepreneurs in a deal brokered by Transworld Business Advisors Nigeria. The transaction, launched January 31 and closed in July 2026, took under six months—a rapid timeline for a regulated pharmaceutical deal. While the company, seller, buyers, and value remain confidential per agreement, Transworld confirmed the business holds active NAFDAC licenses for oral, liquid, and gel drugs with registered product names and intact production equipment, though non-operational at sale.
The deal centered on responsible succession, with the founder seeking retirement rather than letting the licensed asset idle. Transworld structured seller-financing to bridge valuation gaps: the founder received closing liquidity plus a two-year payout schedule, while the acquiring entrepreneurs—bringing adjacent healthcare experience—gained control without paying the full price upfront. This enabled them to activate the facility quickly, avoiding the years typically needed to secure NAFDAC approval and build manufacturing infrastructure from scratch.
Highlighting a growing Entrepreneurship by Acquisition (ETA) trend, the transaction reflects how ageing Nigerian business owners increasingly use formal M&A processes for fair exits while keeping capital-intensive assets productive. It also underscores the value advisors like Transworld bring in regulated sectors through confidential sourcing, deal structuring, and process discipline.
Will more young entrepreneurs pursue acquisition over greenfield starts in healthcare and other regulated sectors, given the time and cost advantages of purchasing dormant licensed facilities?